Check our companion posters on genetic and epigenetic #ctDNA profiling according to PR status in metastatic #breastcancer. 🔴during 1st line ET 🔼 ESR1 promoter methylation in PRpos 🔴after 1st line: 🔼ESR1 mut in PRpos #MBC 🔼GATA3 mut in PRneg #MBC #SABCS23 #liquidbiopsy

#ctDNA is gaining importance in #breastcancer. But what are its real clinical prospects? Excited to share our perspective: 'Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?' 👉 doi.org/10.1080/147371…

Circulating #tumor cells are a promising proxy #biomarker for endocrine #resistance, an emerging propriety deriving from mulitomic alterations. 👉 Here we explore this concept through a combined 🖥️ in-silico and 🧬 in-vivo approach. #liquidbiopsy #bcsm sciencedirect.com/science/articl…

Today we launched the "ISLB Global Survey: Oncologist Attitudes and Practices on Liquid Biopsy" to collect worldwide data on the use of liquid biopsy in clinical practice! Help us sharing the survey with all the oncologists you know :) docs.google.com/forms/d/e/1FAI…

Thrilled to present our poster at #SABCS24 on the use of #ctDNA in monitoring #MetastaticBreastCancer. #LiquidBiopsy RECIST are moving closer to clinical implementation—exciting times for precision oncology!

Understanding mechanisms of resistance to CDK 4/6 inhibitors is crucial to refining the therapeutic algorithm for MBC. Could #liquidbiopsy be the game-changer we need? Find out more in our review, just published in The Breast👇

🏁 Our program on cellular residual disease in triple negative breast cancer is about to launch! Detecting circulating tumor cells in early #TNBC will provide deeper insights into the metastatic process and #immunotherapy response #BreastCancer #LiquidBiopsy #CTC Centro di Riferimento Oncologico

Can #fragmentomics become a new monitoring #biomarker in metastatic breast cancer? 🔬 👉 Here we explore a mutation-agnostic, cost-effective approach tested in the MAGNETIC.1 trial—a longitudinal study of first-line HR+/HER2- MBC. doi.org/10.1016/j.tran…